Zomedica Earnings Reports

Zomedica's Q4 2024 revenue grew to $7.9 million, an 8% increase year-over-year, driven by 109% growth in its Diagnostics segment. The company reported a net loss of $7.2 million, a significant improvement from the $22.4 million net loss in Q4 2023. Gross margin was strong at 70.3%, while non-GAAP adjusted EBITDA loss improved to $5.4 million. Cash and cash equivalents at the end of the quarter stood at $71.4 million, supporting future growth initiatives.

Zomedica reported a 10% increase in revenue to $7.0 million for Q3 2024, driven by strong growth in the Diagnostics segment. The company's gross margin was 72.3%, and it maintains a strong liquidity position of $78 million.

Zomedica reported a strong first quarter in 2024, with revenue up 14% to $6.3 million compared to the same period last year. The company's gross margin was 66%, and it maintained a solid liquidity position with $91 million in cash, cash equivalents, and available-for-sale securities.

Zomedica reported a record fourth quarter with revenue of $7.3 million, contributing to a full-year revenue of $25.2 million, a 33% increase from the previous year. The growth was primarily driven by the Therapeutic Devices segment and the Diagnostics segment. The company's liquidity stood at $100.5 million.

Zomedica reported a record third quarter with a 31% increase in revenue, reaching $6.3 million. The company's gross margin improved to 69%, and it maintained a strong liquidity position with $118 million in cash and cash equivalents. Strategic acquisitions of Structured Monitoring Products and Qorvo Biotechnologies were also completed.

Zomedica reported a 43% increase in revenue to $6.0 million for Q2 2023, driven by growth in both therapeutic and diagnostic segments. The company maintained a strong gross margin of 67% and ended the quarter with $142.4 million in cash, cash equivalents, and available for sale securities.

Zomedica reported a 45% increase in revenue to $5.5 million for Q1 2023, driven by growth in both diagnostic and therapeutic segments. The company maintained a strong gross margin of 70% and ended the quarter with $147.5 million in liquidity.

Zomedica reported a 51% increase in revenue for the fourth quarter of 2022, reaching $6.2 million. The company's gross margin was 70% for the quarter. Zomedica's cash burn during the fourth quarter was $2.5 million.

Zomedica reported a strong third quarter with revenue reaching $4.78 million, a 75% gross margin, and closed the quarter with $158.49 million in cash, cash equivalents, and available-for-sale securities. The company experienced revenue growth driven by both organic sales and recent acquisitions.

Zomedica reported a 51% increase in revenue compared to the previous year, with total revenue reaching $4.2 million. The company's gross margin was 71%, and it ended the quarter with $186.8 million in cash and cash equivalents. Net loss for the quarter was $5.3 million, or $0.005 per share.

Zomedica reported a strong first quarter in 2022, with revenues of $3.8 million, a 74% gross margin, and $192.3 million in cash. Revenue increased by 38% compared to the combined revenues of Zomedica and PulseVet as a standalone company in the same period last year.

Zomedica's total revenue for the Fourth Quarter 2021 was $4.1 million, with PulseVet contributing $4.0 million, a 66% increase over the previous year. The company ended the year with $195 million in cash and cash equivalents.

Zomedica reported its Q3 2021 financial results, showing a net loss of $6.3 million and revenue of $22,514 from TRUFORMA® product sales. The company continued building its TRUFORMA® installed base through the Customer Appreciation Program and focused on business development, leading to the acquisition of Pulse Veterinary Technologies on October 1, 2021.

Zomedica reported a net loss for the three months ended June 30, 2021 of approximately $4.7 million, or $.005 per share. Revenue for the three months ended June 30, 2021 was $15,693 and resulted from the sale of our TRUFORMA® products and associated warranties.

Zomedica reported its Q1 2021 financial results, which included initial revenue of $14,124 from TRUFORMA® product sales. The company reported a net loss of $4.0 million, or $0.04 per share. Zomedica's cash and cash equivalents stood at $276.6 million.

Zomedica, a veterinary health company, reported a net loss of $16.9 million for the year ended December 31, 2020, and no revenues as the company is in the development stage.

Zomedica reported a net loss of $5.0 million for the third quarter of 2020, or $0.01 per share, compared to a loss of $2.8 million, or $0.03 per share, for the same period in 2019. The company's cash position increased to approximately $52.0 million as of September 30, 2020.

Zomedica reported a net loss of $5,307,990 for the second quarter of 2020. The company successfully managed the effects of the coronavirus pandemic and strengthened its balance sheet, while continuing the development and testing of its TRUFORMA™ platform.

Zomedica reported a net loss of $2.45 million, a significant decrease from the $11.68 million loss in the same period last year. The company saw reductions in research and development, general and administrative, and professional fees, while cash and cash equivalents increased due to financing activities.

Zomedica reported a net loss of $19.78 million for the year ended December 31, 2019, with no revenues recorded as the company is in the development stage. The loss was primarily due to research and development expenses, general and administrative expenses, and professional fees. The company is focused on completing the development and commencing commercialization of TRUFORMA™ by the end of 2020.